Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Diabetic Retinopathy

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A year in pharmacology: new drugs approved by the US food and drug administration in 2025.

Naunyn-Schmiedeberg's archives of pharmacology·2026

Same author

β<sub>3</sub>-Adrenoceptor Agonist Effects on the Urinary Bladder Beyond Detrusor Relaxation.

Neurourology and urodynamics·2025

Same author

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024.

Naunyn-Schmiedeberg's archives of pharmacology·2025

Same author

Sacubitril/Valsartan Combination Partially Improves Cardiac Systolic, but Not Diastolic, Function through β-AR Responsiveness in a Rat Model of Type 2 Diabetes.

International journal of molecular sciences·2024

Same author

SGLT2 inhibitors: how do they affect the cardiac cells.

Molecular and cellular biochemistry·2024

Same author

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023.

Naunyn-Schmiedeberg's archives of pharmacology·2024

Search research articles

Related Experiment Video

Updated: May 12, 2026

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

Cardiovascular Dysfunction in Type 2 Diabetes: The Role of MicroRNAs.

Gizem Kayki-Mutlu¹, Ebru Arioglu-Inan²

¹Department of Pharmacology, Faculty of Pharmacy, Ankara University, Ankara, Türkiye.

Handbook of Experimental Pharmacology

|May 11, 2026

Summary

MicroRNAs (miRNAs) are key regulators of cardiovascular dysfunction in type 2 diabetes (T2D). Altered miRNA levels contribute to T2D complications, highlighting their potential as therapeutic targets.

Keywords:

Endothelial dysfunction Heart MicroRNAs Type 2 diabetes Vessels

More Related Videos

Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy

Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy

Published on: December 30, 2025

Related Experiment Videos

Last Updated: May 12, 2026

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy

Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy

Published on: December 30, 2025

Area of Science:

Biochemistry
Molecular Biology
Cardiology

Background:

Type 2 diabetes (T2D) is a significant global health issue.
Cardiovascular dysfunction is a primary cause of morbidity and mortality in T2D patients.
MicroRNAs (miRNAs) are non-coding RNAs that regulate gene expression and are increasingly recognized for their role in T2D complications.

Purpose of the Study:

To discuss the impact of miRNAs on the cardiovascular system in the context of T2D.
To highlight specific miRNAs involved in T2D-related cardiovascular dysfunction.
To explore the potential of miRNAs as therapeutic targets for T2D cardiovascular complications.

Main Methods:

Literature review of studies investigating miRNA involvement in T2D and cardiovascular disease.
Analysis of research on specific miRNAs (e.g., miR-133, miR-1, miR-34a, miR-21, miR-126) in diabetic hearts and vasculature.
Synthesis of evidence regarding miRNA-mediated regulation of cardiac and vascular processes in T2D.

Main Results:

Several miRNAs (miR-133, miR-1, miR-34a, miR-21) are implicated in regulating cardiac hypertrophy, fibrosis, oxidative stress, and cell death in diabetic hearts.
miR-126 is a critical regulator of endothelial function, vascular integrity, and angiogenesis in T2D.
Altered miRNA expression patterns are consistently associated with cardiovascular dysfunction in T2D.

Conclusions:

MicroRNAs play a significant role in the pathogenesis of cardiovascular complications associated with T2D.
Specific miRNAs represent promising biomarkers and therapeutic targets for managing T2D cardiovascular disease.
Further research into miRNA-mediated pathways is crucial for developing novel treatment strategies.